丹仙康骨胶囊对原发性骨质疏松症的临床观察  

Clinical Study of Danxian-Kanggu Capsule in Treating Primary Osteoporosis(POP)

作　　者：黎喜平[1] 沈冯君[1] 陈久毅[1] 方明智[1] 

机构地区：[1]贵阳中医学院一附院骨伤科,贵州贵阳550001

出　　处：《中国中医骨伤科杂志》2003年第4期34-37,共4页Chinese Journal of Traditional Medical Traumatology & Orthopedics

基　　金：贵州省教委科研课题

摘　　要：目的 :评价活血补肾法治疗肝肾亏虚证的原发性骨质疏松症的临床观察。方法 :采用丹仙康骨胶囊治疗 3 5例该病患者 ,治疗前后各测定BMD及有关指标 ,结果 :丹仙康骨胶囊临床显效率及总有效率分别为 43 %和 80 % ,其疗效明显高于对照组 (骨松宝胶囊 )。经双能X线骨密度 (DEXA)证实 ,丹仙康骨胶囊能明显提高原发性骨质疏松症的骨密度。该药还可升高血钙、降低尿钙。结论 :活血补肾法治疗原发性骨质疏松症的作用是通过提高患者的骨密度 ,抑制骨吸收 ,减少骨量丢失等环节实现的。Objective:To assess the effect of Danxian-Kanggu Capsule (DKC) in treating primary osteoporosis.Methods:Through the treating 35 patients with DKC,explore the relative cure index of BMD、S-Ca、U-Ca.Results:The clinical markedly effective and total effetive rates of DKC were 43% and 80%,respectively.The rate of experimental group (DKC plus) is significantly higher of the control group(GU-Songbao Capsule plus).DKC could improve bone mineral density by the verification of double energy X-ray bone density (DEXA).It could also increase the level of serum calcium,decrease the level of urine calcium of 24 hours.Conclusion:The effects of DKC on primary OP included increasing patient's bone mineral density,depressing bone absorption and decreasing bone loss.

关 键 词：活血补肾 丹仙康骨胶囊 原发性骨质疏松症 

分 类 号：R681[医药卫生—骨科学]